GCM
PTGX icon

Ghisallo Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Ghisallo Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-50,000
Closed -$834K – 156
2023
Q3 		$834K Hold
50,000
– – 0.09% 91
2023
Q2 		$1.38M Buy
+50,000
New +$1.25M 0.16% 84

Other funds holding PTGX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Ghisallo Capital Management's PTGX Position: Q4 2023 in Review

Ghisallo Capital Management sold out of Protagonist Therapeutics (PTGX) in Q4 2023, closing a stake of 50,000 shares — an estimated $834K sold.

Ghisallo Capital Management first reported a position in PTGX in Q2 2023 and held it in 2 quarters. The position peaked at $1.38M in Q2 2023. 156 funds tracked by Wall St. Rank hold PTGX as of Q4 2023.

  • Ghisallo Capital Management reported no remaining Protagonist Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Ghisallo Capital Management sold 50,000 Protagonist Therapeutics shares in Q4 2023, an estimated $834K.
  • Ghisallo Capital Management first reported a position in Protagonist Therapeutics in Q2 2023 and held it in 2 quarters.
  • Ghisallo Capital Management's Protagonist Therapeutics position peaked at $1.38M in Q2 2023.
  • 156 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2023.

Based on Ghisallo Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.